Tag: allergy therapeutics

Atopia Therapeutics Reports Preclinical Proof-of-Concept of Lead Compound ATP-R13 in Atopic Dermatitis and Strengthens Patent Protection

  • Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma
  • Positive opinion from the European Patent Office strengthens patent protection of ATP-R13
  • Progress significantly enhances the strategic attractiveness of ATP-R13 as a broadly applicable, disease-modifying therapy across multiple allergic indications

Atopia Therapeutics, a leader in the development of innovative, disease-modifying therapies for allergic and atopic diseases, today announced significant progress in the development of its lead compound ATP-R13. The Company has successfully generated new preclinical in vivo efficacy data supporting the potential of ATP-R13 as a novel oral treatment for atopic dermatitis, an allergic condition commonly known as eczema.

Read more…

Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs

Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.

Read more…